Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

BACKGROUND: Sunitinib malate (SUTENT(®)) is an oral, multitargeted tyrosine kinase inhibitor, approved multinationally for the treatment of advanced RCC and of imatinib-resistant or – intolerant GIST. The purpose of this study was to explore potential biomarkers of sunitinib pharmacological activity...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: DePrimo, Samuel E, Bello, Carlo L, Smeraglia, John, Baum, Charles M, Spinella, Dominic, Rini, Brian I, Michaelson, M Dror, Motzer, Robert J
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2007
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1939830/
https://ncbi.nlm.nih.gov/pubmed/17605814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-5-32
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados